

Erratum

Erratum to Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine* 16:1–7. DOI: 10.1177/11795484221119316

Authors: Rosie S. Jones¹, Patricia S. Smith¹, Paul H. Berg¹, Amparo de la Peña¹, Paul P. Cook², Imad Shawa³, Kathleen M. Kioussopoulos³, Yu Hu¹, Robert J. Schott^{1*}

¹Eli Lilly and Company, Indianapolis, IN, USA

²East Carolina University Brody School of Medicine, Greenville, NC, USA

³Franciscan Alliance, Indianapolis, IN, USA

*Corresponding Author: Robert Schott, Sangamo Therapeutics, Richmond, California, USA.

Email: rschott@sangamo.com

Correction

After publication of the original article,¹ we were notified that an author, Amparo de la Peña, was missing from the PDF version due to an administrative error by SAGE Publications. The revised list of author names has now been corrected in the article PDF and read as follows:

Rosie S. Jones¹, Patricia S. Smith¹, Paul H. Berg¹, Amparo de la Peña¹, Paul P. Cook², Imad Shawa³, Kathleen M. Kioussopoulos³, Yu Hu¹, Robert J. Schott^{1*}

¹Eli Lilly and Company, Indianapolis, IN, USA

²East Carolina University Brody School of Medicine, Greenville, NC, USA

³Franciscan Alliance, Indianapolis, IN, USA

*Current affiliation: Sangamo Therapeutics, Richmond, California, USA; all work carried out while at Eli Lilly and Company

REFERENCE

1. Jones RS, Smith PS, Berg PH, et al. Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. *Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine*. January 2022. doi:10.1177/11795484221119316